CompletedPhase 1NCT04787887

A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers

Studying Gaucher disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
ISU Abxis Co., Ltd.
Principal Investigator
Charlotte Lemech, MD
Scientia Clinical Research Limited
Intervention
Abcertin(drug)
Enrollment
42 enrolled
Eligibility
18-45 years · All sexes
Timeline
2020 – 2020

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04787887 on ClinicalTrials.gov

Other trials for Gaucher disease

Additional recruiting or active studies for the same condition.

See all trials for Gaucher disease →

← Back to all trials